Common Asian Spice Shows Promise in Slowing Progression of Mesothelioma

SpicesIt has recently been discovered that the use of curcumin appears promising in slowing the progression of mesothelioma. As Medical Xpress reports, “Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase levels of a protein inhibitor known to combat the progression of this cancer. Their findings appeared in the Aug. 14 online edition Clinical Cancer Research.”

Medical Xpress goes on to explain, “The culprit in sparking many cancers, particularly mesothelioma, is the intracellular protein and transcription factor STAT3 (signal transducer and activator of transcription 3). A signal transducer and activator is a pathway for instructing the growth and survival of cells, and a transcription factor is a protein that controls genetic information directing cells how to perform. STAT3 is notorious for sending signals to trigger the onset of human cancers and to fuel their continued growth. The great neutralizer of STAT3 is PIAS3 (protein inhibitor of activated STAT3). PIAS3 possesses the strength to inhibit and block STAT3′s ability to cause cancer.”

As the article continues, the logistics of the study are explained in further detail. “Investigators assessed PIAS3 expression in tissue samples of mesothelioma solid tumors and the protein inhibitor’s subsequent effects on STAT3 activity. Tissue samples came from three different locations in the country, and information logged for each specimen detailed how long the patient lived and the types of mesothelioma they had. Investigators then linked the levels of PIAS3 with STAT3 activity in each sample. Additionally, investigators examined the effects of curcumin and peptides extracted from PIAS3 segments on malignant mesothelioma cells in vitro.”

Medical Xpress spoke with Afshin Dowlati, MD, a professor of medicine at Case Western Reserve University School of Medicine and the director of the Center for Cancer Drug Development at University Hospitals Seidman Cancer Center. Dowlati stated, “In those mesothelioma patients where PIAS3 is low, indeed STAT3 is activated. Mesothelioma patients who have low PIAS3 and high STAT3 have a greater chance of dying early. On the flip side, those patients with a high PIAS3 levels have a 44 percent decreased chance of dying in one year, which is substantial.”

In explaining the findings of the study, Medical Xpress continues, “Investigators also found that curcumin and PIAS3 peptides raised PIAS3 levels, which brought down STAT3 activity and caused mesothelioma cells to die. Their study served as proof of principle about the effectiveness of these two compounds in treating malignant mesothelioma, a first step in moving a treatment toward clinical trials. Additionally, their findings demonstrated that PIAS3 could serve as a predictive marker for managing mesothelioma because the disease’s tumors do not always progress in a consistent, predictable manner, even when tumor stages, grades and clinical presentations appear similar.”

Dowlati further explained the results, stating, “Our findings suggest that PIAS3 expression positively affects survival in mesothelioma patients and that PIAS3 activation could become a therapeutic strategy. Our interest for the future is that we want to find better, more simple ways to increase intracellular levels of PIAS3 for malignant mesothelioma through the use of synthetic PIAS3 peptide or curcumin analogs. We must develop a curcumin analog that is absorbable by the human body. Currently, curcumin ingested as the spice turmeric has practically no absorption within the gut.”

Visit Medical Xpress to read the full article.

Mesothelioma Conferences for Patients and Family, and for Scientists

The Mesothelioma Applied Research Foundation will host its 11th International Symposium on Malignant Mesothelioma, as well as a concurrent scientific seminar, on March 5-7, in Alexandria, VA.

Alexandria, VA (PRWEB) January 31, 2014

International Symposium on Malignant Mesothelioma

The Mesothelioma Applied Research Foundation is in the last planning stages of its 11th International Symposium on Malignant Mesothelioma for the mesothelioma community, as well as its first scientific seminar exclusive to scientists, both scheduled to take place on March 5-7, in Alexandria, VA.

This year, the Meso Foundation will be hosting two concurrent events. The International Symposium on Malignant Mesothelioma, a conference for the entire meso community now in its 11th year, will be complemented by a scientific seminar. As always, the Meso Foundation’s Symposium will be geared to attendees from all walks of life, including patients and their families, advocates, medical professionals, and those who have lost a loved one to this disease.

The Mesothelioma Scientific Seminar is a new program for medical professionals only, established this year and chaired by Drs. Richard Alexander of the University of Maryland and Lee Krug of Memorial Sloan-Kettering Cancer Center. In order to encourage and facilitate a high level of information-sharing, collaboration and learning, these sessions are not open to the general public. However, the renowned physicians presenting and attending the Seminar will be available to interact with Symposium attendees outside of their sessions.

For those unable to travel to attend the conference, the Meso Foundation will be live streaming most sessions. The free live stream is a real-time broadcast of the Thursday and Friday sessions of the Symposium. Only a computer (or smart phone/device) and an internet connection are needed to access the live stream, which will be available athttp://www.curemeso.org/symposium. The same webpage also contains the full agenda of the event.

Some of the topics covered during the Symposium and its live stream include pleural and peritoneal mesothelioma, immunotherapy, post-surgical recovery, early detection and biomarkers, cancer stem cells, radiation oncology, chemotherapy: poison or antidote, pulmonary health, translation, comprehensive cancer program development, state of research, chemo brain, survivorship panel, asbestos risks, empowered patient, advocacy and meetings with elected officials, getting involved, and an update on the work of the Meso Foundation.

A detailed agenda of the Mesothelioma Scientific Seminar is available at http://www.curemeso.org/symposium.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,500 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.

Regional Conference on Malignant Mesothelioma: Destination New York

NewYorkSkyline

All of us at the Meso Foundation have been very aware of the need mesothelioma patients and families have to connect with others facing similar challenges, and learn about their disease and its treatment options.

For this reason, for the second consecutive year, we are organizing a regional conference taking place in New York City.

On Friday, September 27, at 9 AM, please join us at the Harvard Club for this one-day conference on malignant mesothelioma for patients, their families, doctors, and others wishing to learn more about this disease. The conference is supported by an educational grant from Levy Phillips & Konigsberg, LLP.

We put together an impressive line-up of mesothelioma experts from the New York area who will discuss topics including standard treatments, ongoing research, environmental/occupational exposure risk, and legal implications. Read the agenda here. 


Register

You can watch below our last year’s conference:

The cost to register is $25 per person (includes all sessions, breakfast and lunch). You may register by visiting curemeso.org/knowledge or by calling the Meso Foundation at (703) 879-3797. Registration fees will be donated back to the Meso Foundation. Availability is limited. You must register before our deadline of September 10.

If you are traveling to the conference and need a hotel room, we put together a list of hotels available nearby. Due to the Clinton Global Initiative annual meeting taking place around the same time as our conference, the hotels near the Harvard Club and throughout New York City could be very expensive, so make sure you book early.